Brightfield Multiplex Immunohistochemistry Assay for PD-L1 Evaluation in Challenging Melanoma Samples.

Autor:	Ugolini F; Section of Pathology, Department of Health Sciences., Tinunin L; Section of Pathology, Department of Health Sciences., Nozzoli F; Section of Pathology, Department of Health Sciences., Simi S; Section of Pathology, Department of Health Sciences., Di Gangi D; Section of Pathology, Department of Health Sciences., Baroni G; Section of Pathology, Department of Health Sciences., Antonini P; Section of Pathology, Department of Health Sciences.; Section of Pathology, Department of Diagnostic and Public Health, University of Verona, Verona, Italy., Szumera-Ciećkiewicz A; Department of Pathology, Maria Sklodowska-Curie National Research Institute of Oncology.; Maria Sklodowska-Curie National Research Institute of Oncology, Biobank, Warsaw, Poland., Massi D; Section of Pathology, Department of Health Sciences.
Jazyk:	angličtina
Zdroj:	Applied immunohistochemistry & molecular morphology : AIMM [Appl Immunohistochem Mol Morphol] 2024 Sep 01; Vol. 32 (8), pp. 389-394. Date of Electronic Publication: 2024 Aug 21.
DOI:	10.1097/PAI.0000000000001219
Abstrakt:	Targeting the PD1/PD-L1 immune checkpoint pathway has rapidly become a therapeutic strategy for melanoma patients. Indeed, the quantification of PD-L1 expression by immunohistochemistry (IHC) in melanoma samples is already required, in some contexts, to allow access to anti-PD-1/PD-L1 immunotherapy. Despite a rising demand for PD-L1 testing, paralleling increasing cumulative experience in its assessment and quantification, it is fair to recognize that PD-L1 evaluation in melanoma samples still presents some critical issues. The aim of this technical report is to develop and validate a multiplex double staining protocol for PD-L1/SOX10 in Ventana Benchmark Ultra for routine practice. Our results show that double labeling provides the necessary tools to identify PD-L1 + melanoma cells clearly. The simultaneous visualization of 2 different proteins targets allows the topographical relationship between the 2 labeling to be evaluated within the context of the tissue morphology. Future studies are needed to test this technique's real-world applicability and effectiveness in implementing interpathologist agreement. Competing Interests: The authors declare no conflict of interest. (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu